FDA approves Tlando an oral testosterone deficiency treatment
Antares Pharma, Inc., a specialty pharmaceutical company, announced that the FDA granted final approval for Tlando(testosterone undecanoate), an oral treatment for testosterone replacement therapy indicated for conditions associated with a deficiency or absence of endogenous testosterone, or hypogonadism in adult males.
Robert F. Apple, President and Chief Executive Officer of Antares Pharma, commented, “The FDA approval of TLANDO brings to market an oral formulation of testosterone that we believe will prove beneficial to physicians and their patients. We have recently expanded our commercial organization to 108 sales representatives and expect to leverage our relationships with urologists and endocrinologists to drive adoption of Tlando". Lipocine licensed the exclusive U.S. commercialization rights for Tlando to Antares Pharma.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.